Circular RNA interference effector molecules (WO10084371)

Expert Opinion on Therapeutic Patents

Volumn 21, Issue 1, 2011, Pages 115-119

  Lundin, Per ^a,b   Moreno, Pedro Md ^b   Smith, Ci Edvard ^b   Andaloussi, Samir El ^b  

^a AlbihnsZacco Stockholm   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Circular interfering RNA; Group I intron; RNAi; SiRNA

Indexed keywords

LOCKED NUCLEIC ACID; PHOSPHOROTHIOIC ACID; SHORT HAIRPIN RNA; SMALL INTERFERING RNA;

ARTICLE; CHEMICAL MODIFICATION; CLINICAL EVALUATION; EXON; HUMAN; INTRON; NONHUMAN; PHYSICAL CHEMISTRY; RNA INTERFERENCE; RNA SPLICING;

GENE SILENCING; HUMANS; PATENTS AS TOPIC; RNA; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 78650445242     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.2011.534460     Document Type: Article

References (31)

1. Fire A, Xu S, Montgomery M, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998;391:806-11
2. Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411:494-8
3. DeVincenzo J, Cehelsky JE, Alvarez R, et al. Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res 2008;77:225-31
4. Davis ME, Zuckerman JE, Choi CH, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010;464(7291):1067-70
5. Leachman SA, Hickerson RP, Schwartz ME, et al. First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol Ther 2010;18:442-6
6. Sahu NK, Shilakari G, Nayak A, Kohli DV. Antisense technology: a selective tool for gene expression regulation and gene targeting. Curr Pharm Biotechnol 2007;8:291-304
7. Ahktar S, Benter I. Non-viral delivery of synthetic siRNAs in vivo. J Clin Invest 2007;117:3623-32
8. Amarzguioui M, Holen T, Babaie E, Prydz H. Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res 2008;31:589-95
9. Czauderna F, Fechtner M, Dames S, et al. Structural variations and stabilizing modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res 2003;31:270516
10. Grunweller A, Wyszko E, Bieber B, et al. Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2'-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res 2003;31:3185-93
11. Mook OR, Baas F, De Wissel MB, Fluiter K. Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo. Mol Cancer Ther 2007;6:833-43
12. Van Den Berg A, Mols J, Han J. RISC-target interaction: cleavage and translational suppression. Biochim Biophys Acta 2008;1779:668-77
13. Abe N, Abe H, Ito Y. Dumbbell-shaped nanocircular RNAs for RNA interference. J Am Chem Soc 2007;129:15108-9
14. Behlke MA. Chemical modification of siRNAs for in vivo use. Oligonucleotides 2008;18:305-19
15. Kennedy S, Wang D, Ruvkun G. A conserved RNA-degrading RNase negatively regulates RNA interference in C. elegans. Nature 2004;427:645-9
16. Haupenthal J, Baehr C, Kiermayer S, et al. Inhibition of RNase A family of enzymes prevents degradation and loss of silencing activity of siRNAs in serum. Biochem Pharmacol 2006;71:702-10
17. Haupenthal J, Baehr C, Zeuzem S, Piiper A. RNase A-like enzymes inhibit the antineoplastic activity of siRNA targeting polo-like kinase 1. Int J Cancer 2007;121:206-10
18. Turner JJ, Jones SW, Moschos SA, et al. MALDI-TOF mass spectral analysis of siRNA degradation in serum confirms an RNase A-like activity. Mol Biosyst 2007;3:43-50
19. Braasch DA, Jensen S, Liu Y, et al. RNA interference in mammalian cells by chemically modified RNA. Biochemistry 2003;42:7967-75
20. Chiu YL, Rana TM. siRNA function in RNAi: a chemical modification analysis. RNA 2003;9:1034-48
21. Puttaraju M, Been MD. Group I permuted intron-exon (PIE) sequences self-splice to produce circular exons. Nucleic Acids Res 1992;20:5357-64
22. Puttaraju M, Perrotta AT, Been MD. A circular trans-acting hepatitis delta virus ribozyme. Nucleic Acids Res 1993;21:4253-8
23. Puttaraju M, Been MD. Generation of nuclease resistant circular RNA decoys for HIV-Tat and HIV-Rev by autocatalytic splicing. Nucleic Acids Symp Ser (Oxf) 1995;33:152-5
24. Umekage S, Kikuchi Y. Production of circular form of streptavidin RNA aptamer in vitro. Nucleic Acids Symp Ser (Oxf) 2006;50:323-4
25. Bohjanen PR, Colvin RA, Puttaraju M, et al. A small circular TAR RNA decoy specifically inhibits Tat-activated HIV-1 transcription. Nucleic Acids Res 1996;24:3733-8
26. Xu MQ, Kathe SD, Goodrich-Blair H, et al. Bacterial origin of a chloroplast intron: conserved self-splicing group I introns in cyanobacteria. Science 1990;250:1566-70
27. Dinter-Gottlieb G. Viroids and virusoids are related to Group I introns. Proc Natl Acad Sci USA 1986;83:6250-4
28. Semple SC, Akinc A, Chen J, et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 2010;28:172-6
29. Love KT, Mahon KP, Levins CG, et al. Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci USA 2010;107:1864-9
30. Elmen J, Thonberg H, Ljungberg K, et al. Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res 2005;33:439-47
31. Kim DH, Behlke MA, Rose SD, et al. Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol 2005;23:222-6